Trevi Therapeutics to Detail Q1 Results Amidst Unmet Cough Treatment Need
Event summary
- Trevi Therapeutics will report Q1 2026 financial results and provide a corporate update on May 5, 2026, at 4:30 p.m. ET.
- The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC.
- Haduvio is the only therapy demonstrating statistically significant cough reduction across IPF and RCC clinical trials.
- Approximately 2-3 million U.S. patients suffer from refractory chronic cough (RCC).
The big picture
Trevi Therapeutics is targeting a significant unmet need in the respiratory therapeutics space, addressing a condition affecting hundreds of thousands of patients with limited treatment options. The company’s focus on a novel mechanism of action (KAMA) and the potential for a first-in-class therapy positions it for substantial market opportunity, but also exposes it to the inherent risks of clinical development and regulatory approval. The company's valuation will be heavily influenced by the outcome of ongoing and future clinical trials.
What we're watching
- Clinical Adoption
- The success of Haduvio will hinge on physician adoption, which will depend on real-world efficacy data beyond the initial clinical trials and its differentiation from existing, albeit inadequate, treatments.
- Regulatory Pathway
- While nalbuphine isn't currently scheduled by the DEA, any potential shift in regulatory classification could significantly impact Haduvio's commercial viability and market access.
- Market Penetration
- Given the prevalence of chronic cough and the lack of approved therapies, Trevi's ability to capture a meaningful share of the patient population will be crucial for long-term financial success.
Related topics